The Bridge Device For Opioid Withdrawal

A revolutionary approach to treating opiate withdrawal.

The Bridge: An FDA Cleared Device to Address Withdrawal Symptoms

It’s not doubt that opioid withdrawal can cause some painfully cruel symptoms. The #1 reason for relapse back to opioids is the FEAR of withdrawal. It’s what stops many from even starting on the road to beating their addiction. They’re getting barraged with a bundle ailments such as:

  • Excessive sweating
  • GI upset, nausea, vomiting
  • Unbearable anxiety
  • Restlessness
  • Agitation
  • Insomnia
  • Joint and muscle pain

To combat this roadblock, INSynergy has been at the forefront of implementing a revolutionary treatment. The NSS-2 Bridge is the first FDA approved device of its kind – its development was pioneered for addiction treatment by Dr. Taca and his team. The Bridge Device can reduce the pain of opioid withdrawal in less than 30 minutes.

In about the time it takes to watch a television program, you can experience relief from the pain of withdrawal. INSynegy can reduce the hardest part of your first phase of recovery…and you can do it in the comfort of your own home.

How the Bridge Device Works

The Bridge Device (about the size of a half dollar) fits discreetly behind the ear. It works by gently sending electrical impulses to areas of the brain and branches of cranial nerves that lead into the spinal cord. 

Bridge Device

During opioid withdrawal, out of control pain signals overwhelm the spinal cord and brain and cause terrible feelings of pain and anxiety. The Bridge Device interferes with these signals can oftentimes reduce 85% of opioid withdrawal symptoms within 30 minutes. University based animal imaging showed a reduction of neuronal firing of the amygdala by 65% with the Bridge Device. The amygdala is a part of the deep brain stem which is responsible for the fear and anxiety response.

The INSynergy-Bridge Protocol

During this period, traditional non-narcotic rescue medications are offered to assure that the detox process is comfortable and successful.  Many people enjoy the fact that they can still live their life with minimal interruption – all while going through what is supposed to be the most difficult steps of their path to recovery. After wearing the device for 5 days, it’s simply discarded…and the next steps toward recovery can be taken.  After a successful detox, VIVITROL can be offered to ones who desire to be opioid free and start laying the groundwork for a successful recovery.

So, if the pain of withdrawal is preventing you from taking that first step, this innovative INSynergy-Bridge Protocol can be your first step in your recovery. 

INSynergy – Your Catalyst for Change

The hardest part of your recovery can rest in our hands. At no other time before now, could you have such have such a chance at success than with what INSynergy can do for you. Now is the time to look forward. You no longer need to dread the thought of detoxing like you once did. Call INSynergy today and start working toward a life you once thought impossible.

Latest News About The Bridge Device

About Opiate Withdrawal

Addiction to opioids, a class of drugs that includes heroin and prescription painkillers such as oxycodone and fentanyl, has skyrocketed in recent years across the United States. About 1.9 million people have prescription painkiller use disorder, and 435,000 are regular users of heroin, according to the U.S. Department of Health and Human Services’ Substance Abuse and Mental Health Services Administration. Once addicted, stopping can be daunting. A body that has become used to regular infusions of a drug will start producing a cascade of physical symptoms if it is denied that drug. Symptoms include muscle aches and pains, diarrhea, shakes and vomiting. Many people who try to quit using the drugs start using again within a few hours if only to ease the pain.

How The Bridge Works

Bridge Device Opioid WithdrawalThe Bridge works by hitting the body where addiction starts: the brain. It uses neuro-modulation, or electrical stimulation of specific areas of the brain interfering with pain signals and reduces firing in an area of the brain linked to fear and anxiety, the amygdala.

The Bridge takes advantage of 4 cranial nerves that are well represented in the auricle (ear). These are Cranial Nerves 5, 7, 9, and 10. These nerves go back to the brainstem and into the spinal cord and disrupts efferent and afferent pain signals.

Such stimulations can provide relief from opioid withdrawal symptoms. Patients can use the device for up to five days during the acute physical withdrawal phase.

The INSynergy-Bridge Protocol which transitions persons in withdrawal from opiates more comfortably onto Vivitrol, a long acting, monthly injection of naltrexone, which is non-addicting and non-divertible. Our studies show that 85% of the symptoms are reduced within 30 minutes and animal model imaging shows a 65% reduction of firing activity in the amygdala, the area of the brain responsible for fear and anxiety.

The device is contraindicated for patients with hemophilia, patients with cardiac pacemakers or those diagnosed with psoriasis vulgaris.

Bridge Device Chart

The Bridge works by hitting the body where addiction starts: the brain. It uses neuro-modulation, or electrical stimulation of specific areas of the brain interfering with pain signals and reduces firing in an area of the brain linked to fear and anxiety, the amygdala.

The Bridge takes advantage of 4 cranial nerves that are well represented in the auricle (ear). These are Cranial Nerves 5, 7, 9, and 10. These nerves go back to the brainstem and into the spinal cord and disrupts efferent and afferent pain signals.

Such stimulations can provide relief from opioid withdrawal symptoms. Patients can use the device for up to five days during the acute physical withdrawal phase.

The INSynergy-Bridge Protocol which transitions persons in withdrawal from opiates more comfortably onto Vivitrol, a long acting, monthly injection of naltrexone, which is non-addicting and non-divertible. Our studies show that 85% of the symptoms are reduced within 30 minutes and animal model imaging shows a 65% reduction of firing activity in the amygdala, the area of the brain responsible for fear and anxiety.

The device is contraindicated for patients with hemophilia, patients with cardiac pacemakers or those diagnosed with psoriasis vulgaris.

American Journal of Drug and Alcohol AbuseNeuromodulation with percutaneous electrical nerve field stimulation is associated with reduction in signs and symptoms of opioid withdrawal: a multisite, retrospective assessment

by Adrian Miranda, MD and Arturo Taca Jr., MD

Finding an effective, non-pharmacological approach to treat opioid withdrawal could remove some of the barriers associated with pharmacotherapy. The BRIDGE® is a noninvasive, percutaneous electrical nerve field stimulator developed to target pain.

This pilot study aimed to determine (1) the effects of the BRIDGE on withdrawal scores during the induction phase of opioid withdrawal therapy, (2) the percentage of subjects who successfully transitioned to medication assisted therapy (MAT).

Learn more…

Neuromodulation with percutaneous electrical nerve field stimulation is associated with reduction in signs and symptoms of opioid withdrawal: a multisite, retrospective assessment

by Adrian Miranda, MD and Arturo Taca Jr., MD

Finding an effective, non-pharmacological approach to treat opioid withdrawal could remove some of the barriers associated with pharmacotherapy. The BRIDGE® is a noninvasive, percutaneous electrical nerve field stimulator developed to target pain.

This pilot study aimed to determine (1) the effects of the BRIDGE on withdrawal scores during the induction phase of opioid withdrawal therapy, (2) the percentage of subjects who successfully transitioned to medication assisted therapy (MAT).

Learn more…